Education
About Us
Working with TipRanks
Follow Us
Ionis Pharmaceuticals Inc. (IONS)
:IONS
IONS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$30.23 - $52.34
Previous CloseN/A
Volume126.35K
Average Volume (3M)1.71M
Market Cap
$5.04B
Enterprise Value$5.18B
Total Cash (Recent Filing)$242.08M
Total Debt (Recent Filing)$1.42B
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Apr 30, 2025EPS Estimate
-1.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.04
Shares Outstanding158,964,770
10 Day Avg. Volume1,455,331
30 Day Avg. Volume1,713,903
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)7.42
Price to Cash Flow (P/CF)-11.30
P/FCF Ratio0.00
Enterprise Value/Market Cap1.03
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit7.46
Enterprise Value/Ebitda-14.46
Forecast
1Y Price Target
$57.24Price Target Upside80.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe deal provides IONS with $280 million upfront and up to $660 million in development, regulatory, and sales milestones, plus royalties on net sales.
Growth ProspectsAnalyst raises the price target for IONS from $52 to $55, reflecting confidence in the company's growth prospects.
License AgreementIONS announced a license agreement with Ono for exclusive global development and commercialization rights to sapablursen, which will bring significant upfront payments and potential future milestones.
Bears Say
Clinical TrialsSapablursen was evaluated in beta thalassemia, though its Phase II trial was terminated due to underwhelming efficacy.
Development DelaysThe highly-anticipated Pelacarsen readout has been delayed, making the sHTG readout the only major catalyst for 2025.
Revenue Guidance2025 revenue guidance reflects an approximate 15% year-over-year decline, accounting for decreasing R&D revenues.
---
Ownership Overview
0.74% Insiders
39.51% Mutual Funds
0.23% Other Institutional Investors
44.65% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IONS FAQ
What was Ionis Pharmaceuticals Inc.’s price range in the past 12 months?
Ionis Pharmaceuticals Inc. lowest stock price was $30.23 and its highest was $52.34 in the past 12 months.
What is Ionis Pharmaceuticals Inc.’s market cap?
Ionis Pharmaceuticals Inc.’s market cap is $5.04B.
When is Ionis Pharmaceuticals Inc.’s upcoming earnings report date?
Ionis Pharmaceuticals Inc.’s upcoming earnings report date is Apr 30, 2025 which is in 32 days.
How were Ionis Pharmaceuticals Inc.’s earnings last quarter?
Ionis Pharmaceuticals Inc. released its earnings results on Feb 19, 2025. The company reported -$0.66 earnings per share for the quarter, beating the consensus estimate of -$1.124 by $0.464.
Is Ionis Pharmaceuticals Inc. overvalued?
According to Wall Street analysts Ionis Pharmaceuticals Inc.’s price is currently Undervalued.
Does Ionis Pharmaceuticals Inc. pay dividends?
Ionis Pharmaceuticals Inc. does not currently pay dividends.
What is Ionis Pharmaceuticals Inc.’s EPS estimate?
Ionis Pharmaceuticals Inc.’s EPS estimate is -1.08.
How many shares outstanding does Ionis Pharmaceuticals Inc. have?
Ionis Pharmaceuticals Inc. has 158,964,770 shares outstanding.
What happened to Ionis Pharmaceuticals Inc.’s price movement after its last earnings report?
Ionis Pharmaceuticals Inc. reported an EPS of -$0.66 in its last earnings report, beating expectations of -$1.124. Following the earnings report the stock price went down -0.438%.
Which hedge fund is a major shareholder of Ionis Pharmaceuticals Inc.?
Currently, no hedge funds are holding shares in IONS
---
Ionis Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$57.24 (80.45% Upside)
$57.24 (80.45% Upside)
Blogger Sentiment
Bullish
IONS Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 426.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $705.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 9.1%
Last 30 Days ▼ 9.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.97%
12-Months-Change
Fundamentals
Return on Equity
-93.03%
Trailing 12-Months
Asset Growth
0.45%
Trailing 12-Months
Company Description
Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
---
IONS Company Deck
---
IONS Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted Ionis Pharmaceuticals' successful launch of Tringolza and strong financial performance, with plans for future product launches and positive market response for existing products like WAYLIVRA. However, challenges remain in patient identification and clinical outcomes, as well as a decline in R&D revenue. The positive developments and strategic plans outweigh the challenges, indicating a positive outlook.Read More>---
IONS Revenue Breakdown
60.82% R&D
39.18% Commercial
---
IONS Stock 12 Month Forecast
Average Price Target
$57.24
▲(80.45% Upside)
Technical Analysis
Best Analysts Covering IONS
1 Year
1 Year Success Rate
11/17 ratings generated profit
1 Year Average Return
+13.51%
reiterated a buy rating last month
Copying Gary Nachman's trades and holding each position for 1 Year would result in 64.71% of your transactions generating a profit, with an average return of +13.51% per trade.
---